PMD4U - Standardising quantification and susceptibility testing of phages

The aim of this project is to develop a market-validated minimum viable product (MVP) for rapid, automated and standardised bacteriophage quantification and susceptibility testing within a One Health approach. The MVP builds on our core microfluidic technology, which 
is currently not yet ready for market validation. Within this project, the technology will be further developed into an integrated platform that meets concrete market expectations and
allowing future integration into automated workflows. In this way, we aim to reduce the development risk and prepare the technology for further upscaling, licensing and distribution 
by commercial partners and investors.